A Phase II, Signal-Seeking Trial of the Clinical Benefit Rate Associated with Pamiparib in Subjects with Germline or Somatic BRCA1/2 High Grade Serous Ovarian Cancer or carcinosarcoma who have progressed on P-gp substrate chemotherapy or PARP inhibitors with the Presence of an ABCB1 Fusion and the Absence of a BRCA1/2 Reversion

Project: Research

AcronymPRECISE
StatusActive
Effective start/end date20/09/1919/09/24

Keywords

  • clinical trial
  • phase 2 study
  • treatment efficacy
  • ovarian cancer